Format

Send to:

Choose Destination
See comment in PubMed Commons below
Arch Neurol. 2005 Sep;62(9):1428-31.

A "malignant" variant of status epilepticus.

Author information

  • 1Department of Neurology, Charit√© -- Universit√§tsmedizin Berlin, Auguste-Viktoria-Krankenhaus Berlin, Germany. martin.holtkamp@charite.de

Abstract

BACKGROUND:

Status epilepticus (SE) frequently does not respond to common first-line anticonvulsants. In a substantial portion of patients, administration of anticonvulsant anesthetics is inevitable. Even this aggressive approach fails to terminate SE in an undefined number of cases. We have coined the term malignant SE for this most severe variant of SE.

OBJECTIVE:

To assess frequency, risk factors, and in-hospital outcome of malignant SE.

DESIGN:

Retrospective cohort study.

SETTING:

Neurologic intensive care unit of a large university hospital. Patients Sample of 35 episodes of SE not responding to first-line anticonvulsants in 34 patients.

MAIN OUTCOME MEASURES:

Predictive and prognostic features of episodes of malignant SE with persistent epileptic activity after high-dose anesthetics compared with features of the remainder of cases with refractory SE and persistent epileptic activity after failure of first-line anticonvulsants.

RESULTS:

Status epilepticus that could not be controlled by first-line anticonvulsants resulted in malignant SE in 20% of cases. Patients with malignant SE were significantly younger than patients with refractory SE (P = .03). Encephalitis was identified as an independent risk factor for malignant SE (P = .008). Outcome in malignant SE was poor, with significantly longer duration of seizure activity (P<.001), longer stay in the neurologic intensive care unit (P<.001) and in the hospital (P = .007), and more patients with functional dependency at discharge from the hospital (P = .04).

CONCLUSIONS:

Malignant SE is not rare after failure of first-line anticonvulsants. The patient at risk is typically young and suffers from encephalitis. Such patients should be treated aggressively early in the course of SE to prevent malignant SE.

PMID:
16157750
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Write to the Help Desk